DNAnexus
PrivateLast Round
Series I
Mar 8, 2022
Est. Valuation
$600M
Total Funding Raised
$472.55M
Company Overview
DNAnexus is a healthcare software company that provides a secure, cloud-based platform for biomedical informatics and data management to accelerate precision health and scientific discovery.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Cloud Infrastructure, Data Integration, Drug Discovery
Business Model
B2B
Customer Profile
Usage-Based SaaS, Subscription SaaS, Government Contracts, Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DNAnexus Comparables
Compare DNAnexus with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Velsera | 85% | |
| Lifebit | 79% | |
| Danaher | 78% |
DNAnexus Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series I | Mar 8, 2022 | ||||
| Series G | Jun 9, 2020 | ||||
| Series F | Feb 6, 2019 | ||||
| Series E | Jan 2, 2018 | ||||
| Series D | Apr 22, 2015 | ||||
Series C | Jan 3, 2014 |
Key People
Founding team and executive leadership
DNAnexus Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Uncork Capital | Seed, Series B |
| Innovatus Capital Partners | Series I, Series F |
| GV | Series E, Series I, Series G, Series C, Series F, Series B |
| Perceptive Advisors | Series I, Series G |
| M12 - Microsoft's Venture Fund | Series E |
| Northpond Ventures | Series I, Series G |
| Foresite Capital | Series I, Series G, Series E, Series F |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 28, 2025
Dr. Oakland departs as VP and Product Lead for precision oncology.
- Aug 28, 2025
Dr. Oakland joins as VP and Product Lead.
Recent news
Latest coverage and updates
- recognized_asAug 11, 2026
DNAnexus Inc. recognized as 2026 Inc. 5000 on Aug 11th '26.
DNAnexus Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about DNAnexus's valuation, stock price, and market status.
Is DNAnexus a public or private company?
DNAnexus is a private company.
What is the current stock price of DNAnexus?
DNAnexus is a private company with no public stock price. No recent secondary market data is available.
How much is DNAnexus worth (valuation)?
DNAnexus's valuation is estimated at $600.0M based on funding round data.
Can I buy DNAnexus stock?
DNAnexus shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was DNAnexus's last funding round?
DNAnexus's most recent funding round was Series I on March 8, 2022.
Who are the main investors in DNAnexus?
Key investors in DNAnexus include GV, Perceptive Advisors, Northpond Ventures, Foresite Capital, First Round Capital.
Will DNAnexus IPO soon?
No public IPO plans have been announced for DNAnexus.
How can I track DNAnexus secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor DNAnexus's secondary market activity and sign up for updates.